Savara (SVRA) Total Liabilities (2010 - 2026)
Savara (SVRA) posted quarterly Total Liabilities of $45.6 million for Q1 2026, up 9.98% year-over-year from $41.5 million in Q1 2025, and down 9.34% quarter-over-quarter from $50.3 million in Q4 2025.
Savara (SVRA) Total Liabilities (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Total Liabilities for 17 consecutive years, with $45.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 9.98% year-over-year to $45.6 million; the TTM figure through Mar 2026 stood at $45.6 million (up 9.98% YoY), while the FY2025 annual figure was $50.3 million, up 21.42% from the prior year.
- Total Liabilities declined to $45.6 million in Q1 2026 per SVRA's latest filing, from $50.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $50.3 million in Q4 2025 and bottomed at $29.7 million in Q1 2022.
- Historically, Total Liabilities has averaged $37.7 million across 5 years, with a median of $37.2 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities decreased 8.54% — and 2025, when it advanced 21.42%.
- Savara's Total Liabilities stood at $32.0 million in 2022, then climbed by 16.23% to $37.2 million in 2023, then rose by 11.39% to $41.4 million in 2024, then rose by 21.42% to $50.3 million in 2025, then decreased by 9.34% to $45.6 million in 2026.
- Business Quant data shows SVRA's Total Liabilities at $45.6 million in Q1 2026, $50.3 million in Q4 2025, and $46.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 48.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.48 Mn |
| Mar 31, 2026 | 45.61 Mn |
| Dec 31, 2025 | 50.30 Mn |
| Sep 30, 2025 | 46.54 Mn |
| Jun 30, 2025 | 43.28 Mn |
| Mar 31, 2025 | 41.47 Mn |
| Dec 31, 2024 | 41.43 Mn |
| Sep 30, 2024 | 39.47 Mn |
| Jun 30, 2024 | 37.94 Mn |
| Mar 31, 2024 | 36.43 Mn |
| Dec 31, 2023 | 37.19 Mn |
| Sep 30, 2023 | 35.53 Mn |
| Jun 30, 2023 | 32.12 Mn |
| Mar 31, 2023 | 31.10 Mn |
| Dec 31, 2022 | 32.00 Mn |
| Sep 30, 2022 | 31.24 Mn |
| Jun 30, 2022 | 29.74 Mn |
| Mar 31, 2022 | 29.73 Mn |
| Dec 31, 2021 | 32.10 Mn |
| Sep 30, 2021 | 32.05 Mn |